Full Text:   <1439>

Summary:  <664>

Suppl. Mater.: 

CLC number: 

On-line Access: 2021-12-14

Received: 2021-05-09

Revision Accepted: 2021-08-16

Crosschecked: 0000-00-00

Cited: 0

Clicked: 2384

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Xin QI

https://orcid.org/0000-0001-9038-4287

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2021 Vol.22 No.12 P.1053-1059

http://doi.org/10.1631/jzus.B2100412


Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer


Author(s):  Xin QI, Donghui YAN, Jiachen ZUO, Rui WANG, Jiajia CHEN

Affiliation(s):  School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China

Corresponding email(s):   qixin@usts.edu.cn

Key Words:  Chemokine signaling, Multigene signature, Colorectal cancer, Prognosis, Therapeutic response


Xin QI, Donghui YAN, Jiachen ZUO, Rui WANG, Jiajia CHEN. Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer[J]. Journal of Zhejiang University Science B, 2021, 22(12): 1053-1059.

@article{title="Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer",
author="Xin QI, Donghui YAN, Jiachen ZUO, Rui WANG, Jiajia CHEN",
journal="Journal of Zhejiang University Science B",
volume="22",
number="12",
pages="1053-1059",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2100412"
}

%0 Journal Article
%T Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer
%A Xin QI
%A Donghui YAN
%A Jiachen ZUO
%A Rui WANG
%A Jiajia CHEN
%J Journal of Zhejiang University SCIENCE B
%V 22
%N 12
%P 1053-1059
%@ 1673-1581
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2100412

TY - JOUR
T1 - Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer
A1 - Xin QI
A1 - Donghui YAN
A1 - Jiachen ZUO
A1 - Rui WANG
A1 - Jiajia CHEN
J0 - Journal of Zhejiang University Science B
VL - 22
IS - 12
SP - 1053
EP - 1059
%@ 1673-1581
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2100412


Abstract: 
colorectal cancer (CRC) is the most lethal gastrointestinal cancer in both males and females worldwide (Sung et al., 2021). Because of the high heterogeneity of tumors, robust prognostic biomarkers are urgently needed in CRC management (Koncina et al., 2020). chemokine signaling is a well-known pivotal player in immunity, inflammation, and cancer metastasis (Lacalle et al., 2017; Poeta et al., 2019; Do et al., 2020), and multiple genes involved in chemokine signaling have been demonstrated as potential prognostic biomarkers for CRC (Cabrero-De Las Heras and Martínez-Balibrea, 2018; Ottaiano et al., 2020; Yu et al., 2020). Therefore, the aim of our study was to develop a chemokine signaling-based multigene signature (CSbMgSig) that could effectively predict overall survival (OS) and therapeutic response for patients with CRC.

基于趋化因子信号通路开发新型多基因模型用于预测结直肠癌的预后和治疗反应

目的:开发一种基于趋化因子信号通路的多基因模型,可以有效预测结直肠癌患者的总生存期和治疗反应。
创新点:结直肠癌具有高度异质性,迫切需要开发可靠的标志物用于预测患者的预后和治疗效果。研究显示趋化因子信号通路关键基因表达变化与结直肠癌转移和预后密切相关,但尚缺乏基于该信号通路的基因模型用来预测患者的临床预后。本研究基于趋化因子信号通路构建了一种新的多基因模型(CSbMgSig),用于结直肠癌患者的预后风险分层和总体生存时间预测,为结直肠癌患者的治疗提供指导。
方法:首先,考虑到转移对结直肠癌预后的重要影响,我们在原发和转移性结直肠癌样本中鉴定了差异表达的趋化因子信号通路相关基因。然后,结合单因素Cox回归分析和LASSO Cox回归分析建立基于趋化因子信号通路的预后模型CSbMgSig,并在另一个独立数据集通过Kaplan-Meier生存分析和时间依赖性受试者工作特征(ROC)分析进一步验证其预后性能。此外,我们还进行了基因本体(GO)富集分析、基因集富集分析(GSEA)、单样本基因集富集分析(ssGSEA)和化疗反应分析,以探索CSbMgSig在结直肠癌致病机制中的功能及其对免疫浸润和化疗反应的影响。
结论:构建的由8个趋化因子信号通路相关基因组成的预后模型CSbMgSig,可以有效地在训练集和验证集中区分高危结直肠癌患者,并被证明是总生存期的独立预测因子。功能分析结果表明,该特征在结直肠癌患者的免疫浸润和对药物的反应中起关键作用。因此,基于趋化因子信号通路的多基因模型CSbMgSig是一种很有前景的工具,可以进行风险分层、生存预测和治疗评估,从而有利于结直肠癌患者的个性化管理。

关键词:趋化因子信号;多基因模型;结直肠癌;预后;治疗反应

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Cabrero-de Las HerasS, Martínez-BalibreaE, 2018. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol, 24(42):4738-4749.

[2]DoHTT, LeeCH, ChoJ, 2020. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers, 12(2):287.

[3]GlimeliusB, StintzingS, MarshallJ, et al., 2021. Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev, 98:102218.

[4]IchikawaN, KamiyamaT, YokooH, et al., 2020. Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis. Mol Clin Oncol, 12(4):374-383.

[5]KamalY, SchmitSL, HoehnHJ, et al., 2019. Transcriptomic differences between primary colorectal adenocarcinomas and distant metastases reveal metastatic colorectal cancer subtypes. Cancer Res, 79(16):4227-4241.

[6]KoncinaE, HaanS, RauhS, et al., 2020. Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges. Cancers, 12(2):319.

[7]KurzejamskaE, SacharczukM, LandázuriN, et al., 2019. Effect of chemokine (C-C motif) ligand 7 (CCL7) and its receptor (CCR2) expression on colorectal cancer behaviors. Int J Mol Sci, 20(3):686.

[8]LacalleRA, BlancoR, Carmona-RodríguezL, et al., 2017. Chapter five‍‒‍chemokine receptor signaling and the hallmarks of cancer. Int Rev Cell Mol Biol, 331:181-244.

[9]MarisaL, de ReynièsA, DuvalA, et al., 2013. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med, 10(5):e1001453.

[10]OttaianoA, ScalaS, NormannoN, et al., 2020. Prognostic and predictive role of CXC chemokine receptor 4 in metastatic colorectal cancer patients. Appl Immunohistochem Mol Morphol, 28(10):755-760.

[11]PoetaVM, MassaraM, CapucettiA, et al., 2019. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol, 10:379.

[12]QiX, WangR, LinYX, et al., 2021. A ferroptosis-related gene signature identified as a novel prognostic biomarker for colon cancer. Front Genet, 12:692426.

[13]SungH, FerlayJ, SiegelRL, et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209-249.

[14]YangW, SoaresJ, GreningerP, et al., 2013. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res, 41(D1):D955-D961.

[15]YuL, YangXM, XuCC, et al., 2020. Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer. Int Immunopharmacol, 89:107077.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE